68Ga-NEB ( DrugBank: - )
3 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 46 | Malignant rheumatoid arthritis | 1 |
| 89 | Lymphangioleiomyomatosis | 1 |
| 280 | Huge arteriovenous malformation with cervicofacial or limb lesion | 1 |
46. Malignant rheumatoid arthritis
Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04273334 (ClinicalTrials.gov) | October 1, 2019 | 15/2/2020 | Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders | Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders, Including Lymphedema, Lymphangioma, Lymphangioleiomyomatosis, Plastic Bronchitis, Lymphadenopathy Caused by Rheumatoid Arthritis, Etc. | Lymphatic Disorders | Drug: 68Ga-NEB | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | 80 Years | All | 90 | Phase 1 | China |
89. Lymphangioleiomyomatosis
Clinical trials : 38 / Drugs : 38 - (DrugBank : 15) / Drug target genes : 18 - Drug target pathways : 118
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04273334 (ClinicalTrials.gov) | October 1, 2019 | 15/2/2020 | Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders | Application of 68Ga NEB PET Imaging in the Diagnosis and Evaluation of Lymphatic Disorders, Including Lymphedema, Lymphangioma, Lymphangioleiomyomatosis, Plastic Bronchitis, Lymphadenopathy Caused by Rheumatoid Arthritis, Etc. | Lymphatic Disorders | Drug: 68Ga-NEB | Peking Union Medical College Hospital | NULL | Recruiting | 18 Years | 80 Years | All | 90 | Phase 1 | China |
280. Huge arteriovenous malformation with cervicofacial or limb lesion
Clinical trials : 27 / Drugs : 30 - (DrugBank : 15) / Drug target genes : 14 - Drug target pathways : 153
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02496013 (ClinicalTrials.gov) | January 2014 | 6/7/2015 | Clinical Translation of a Novel Albumin-Binding PET Radiotracer 68Ga-NEB | Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Diagnostic Performance of 68Ga-NEB in Healthy Volunteers and Patients With Hepatic Space-occupying Lesions and Suspicious Lymph Nodes Metastasis | Arteriovenous Malformation;Hemangioma;Neoplasms Lymph Nodes;Lymphedema | Drug: 68Ga-NEB | Peking Union Medical College Hospital | National Institute for Biomedical Imaging and Bioengineering (NIBIB) | Recruiting | 18 Years | N/A | All | 70 | Phase 1 | China |